HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prognostic factors for curative pelvic exenterations in patients with recurrent uterine cervical or vaginal cancer.

AbstractOBJECTIVES:
The aim of this study was to assess the prognostic factors after curative pelvic exenterations performed for recurrent uterine cervical or vaginal cancers in the era of concomitant chemoradiotherapy.
METHODS:
We retrospectively enrolled 16 patients with recurrent uterine cervical or vaginal cancer and tumor-free resection margins on pelvic exenteration pathological analysis between October 1997 and April 2014.
RESULTS:
Pelvic exenterations were performed for 13 recurrent cervical cancers and 3 recurrent vaginal cancers. All of the patients had received pelvic irradiation (external radiotherapy for 14 patients and brachytherapy for 2 patients). The median age at the recurrence was 59.5 years (49-77 years), and the median tumor size was 4.35 cm (2-9 cm). There were no intraoperative or postoperative deaths. The 5-year disease-free survival and overall survival were 30% and 34.1%, respectively. The following 3 factors affected the disease-free survival: tumor size greater than 5 cm (P = 0.05), mesorectal lymph node involvement (P = 0.02), and vascular emboli (P = 0.0093).
CONCLUSIONS:
The presence of vascular emboli is a new prognostic factor in cases of recurrent cervical or vaginal cancer. Assessing the presence of vascular emboli on pretherapeutic biopsies could facilitate the selection of patients eligible for curative pelvic exenterations.
AuthorsHugo Sardain, Vincent Lavoué, Bruno Laviolle, Sébastien Henno, Fabrice Foucher, Jean Levêque
JournalInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society (Int J Gynecol Cancer) Vol. 24 Issue 9 Pg. 1679-85 (Nov 2014) ISSN: 1525-1438 [Electronic] England
PMID25254565 (Publication Type: Journal Article)
Topics
  • Adenocarcinoma (mortality, pathology, surgery)
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Brachytherapy
  • Carcinoma, Squamous Cell (mortality, pathology, surgery)
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local (mortality, pathology, surgery)
  • Neoplasm Staging
  • Pelvic Exenteration (methods)
  • Postoperative Complications (prevention & control)
  • Prognosis
  • Retrospective Studies
  • Survival Rate
  • Uterine Cervical Neoplasms (mortality, pathology, surgery)
  • Vaginal Neoplasms (mortality, pathology, surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: